Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xu Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0238-543X; OpenAlex author ID A5083405314. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 18

  1. Preoperative prediction of early recurrence in pancreatic cancer: A novel clinical-radiomics model. Co-author DOI 10.1002/ijc.70142↗
  2. Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. Co-author DOI 10.1016/j.isci.2024.111693↗
  3. Deciphering molecular crosstalk mechanisms between skeletal muscle atrophy and KRAS-mutant pancreatic cancer: a literature review. Co-author DOI 10.21037/hbsn-24-282↗
  4. IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41401-022-01035-w↗
  5. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Co-author DOI 10.1038/s41591-023-02640-w↗
  6. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer. Co-author DOI 10.1002/path.5588↗
  7. Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis. Co-author DOI 10.1080/15384101.2021.1874684↗
  8. DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. Co-author DOI 10.1111/jcmm.16196↗
  9. HEATR1 Deficiency Promotes Chemoresistance via Upregulating ZNF185 and Downregulating SMAD4 in Pancreatic Cancer. First author DOI 10.1155/2020/3181596↗
  10. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Co-author DOI 10.1007/s10238-018-00543-6↗
  11. Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo. Co-author DOI 10.1016/j.yexcr.2019.111605↗
  12. Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway. Co-author DOI 10.1111/bph.13718↗
  13. BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity. Co-author DOI 10.18632/oncotarget.17965↗
  14. Overexpression of miR-135b-5p promotes unfavorable clinical characteristics and poor prognosis via the repression of SFRP4 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.19150↗
  15. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Co-author DOI 10.1097/mpa.0000000000000501↗
  16. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.1097/mpa.0000000000000520↗
  17. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.4506↗
  18. [Effect of 5-aza-2'-deoxycytidine on growth and methylation of RUNX3 gene in human pancreatic cancer cell line MiaPaca2]. Co-author DOI 10.3760/cma.j.issn.0253-3766.2013.01.004↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianang Li · 5 shared papers, 2016–2025 · strength 0.64
  2. Wenhui Lou · 5 shared papers, 2017–2025 · strength 0.58
  3. Hexige Saiyin · 6 shared papers, 2015–2023 · strength 0.58
  4. Yuan Fang · 6 shared papers, 2015–2021 · strength 0.56
  5. Tiantao Kuang · 5 shared papers, 2017–2021 · strength 0.54
  6. Dansong Wang · 3 shared papers, 2019–2025 · strength 0.45
  7. Wenhui Lou · 5 shared papers, 2015–2021 · strength 0.44
  8. Haokang Feng · 2 shared papers, 2025 · strength 0.43
  9. Huaxiang Xu · 2 shared papers, 2025 · strength 0.43
  10. Yuquan Guo · 2 shared papers, 2025 · strength 0.43
  11. Yefei Rong · 4 shared papers, 2017–2021 · strength 0.41
  12. Yaolin Xu · 2 shared papers, 2021–2025 · strength 0.36
  13. Lixiang Ma · 2 shared papers, 2021–2023 · strength 0.32
  14. Yiting Xu · 1 shared paper, 2026 · strength 0.24
  15. Qi Zhang · 1 shared paper, 2026 · strength 0.24
  16. Tingbo Liang · 1 shared paper, 2026 · strength 0.24
  17. Weisheng Yu · 1 shared paper, 2025 · strength 0.22
  18. Wenhui Lou · 1 shared paper, 2025 · strength 0.22
  19. Hanlin Yin · 1 shared paper, 2025 · strength 0.21
  20. Liang Liu · 1 shared paper, 2025 · strength 0.21
  21. Hua Su · 1 shared paper, 2025 · strength 0.21
  22. Lei Zhang · 1 shared paper, 2025 · strength 0.21
  23. Runjie Liu · 1 shared paper, 2025 · strength 0.21
  24. Yuan Fang · 2 shared papers, 2016–2021 · strength 0.18
  25. Hada Buhe · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.